P/E ratio for AstraZeneca (AZN)

P/E ratio history for AstraZeneca from 2001 to 2025

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Bristol-Myers Squibb BMY	18.3	-39.34%	🇺🇸 USA
Pfizer PFE	14.8	-50.69%	🇺🇸 USA
Merck MRK	12.9	-57.01%	🇺🇸 USA
GlaxoSmithKline GSK	13.6	-54.93%	🇬🇧 UK
Sanofi SNY	12.8	-57.47%	🇫🇷 France
Eli Lilly LLY	51.4	70.71%	🇺🇸 USA
Johnson & Johnson JNJ	20.0	-33.39%	🇺🇸 USA
Abbott Laboratories ABT	15.7	-47.69%	🇺🇸 USA
Biogen BIIB	15.6	-48.15%	🇺🇸 USA
Novartis NVS	18.3	-39.05%	🇨🇭 Switzerland

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.